Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer

Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival

(2014) Shi-Yi Wang et al.   BREAST CANCER RESEARCH AND TREATMENT

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

(2014) Evandro de Azambuja et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

(2014) Ghideon Ezaz et al.   Journal of the American Heart Association

Independent and Incremental Value of Deformation Indices for Prediction of Trastuzumab-Induced Cardiotoxicity

(2013) Kazuaki Negishi et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

(2013) Aron Goldhirsch et al.   LANCET

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

(2013) Xavier Pivot et al.   LANCET ONCOLOGY

Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 – a prospective study

(2012) Grzegorz Piotrowski et al.   Archives of Medical Science

Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial

(2012) Siri Lagethon Heck et al.   CARDIOLOGY

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2012) Edward H. Romond et al.   JOURNAL OF CLINICAL ONCOLOGY

Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI

(2011) Edith Pituskin et al.   BMC CANCER

Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer

(2011) Luigi Tarantini et al.   JOURNAL OF CARDIAC FAILURE

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery

(2010) L.J. Murray et al.   BREAST

Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial

(2010) Marion Procter et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

(2010) Daniela Cardinale et al.   JOURNAL OF CLINICAL ONCOLOGY